Contact lens and contact lens product

Abstract

To provide a contact lens and a contact lens product.SOLUTION: A contact lens is provided which includes a humectant including glucan. The glucan in a component of the contact lens includes 1,3-1,6-glucan or beta-glucan. This can reduce dissipation of water to air from the contact lens and contributes to an improvement in maintaining humidity in the contact lens.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to contact lenses and contact lens products, and particularly to contact lenses and contact lens products having excellent moisture retention properties.

Background Art

[0002] Contact lenses have different water contents depending on the composition of the material. When a user wears a contact lens, moisture on the surface of the eyeball is absorbed by the contact lens to supplement the moisture dissipated from the contact lens to the air, and the dissipation of moisture increases with the passage of wearing time. Therefore, when a user wears a contact lens for a long time, the eyes become dry, causing uncomfortable symptoms such as redness, swelling, and heat. In order to improve the comfort of long-term wear for users and enhance the purchase intention of users for contact lens products, it is necessary to effectively reduce the moisture dissipation of contact lenses.

Summary of the Invention

[0003] The present disclosure provides a contact lens and a contact lens product that can reduce the moisture dissipation from the contact lens to the air by using a glucan having a high moisture retention effect as a moisturizing agent in the contact lens, and contribute to the improvement of the moisture retention ability of the contact lens.

[0004] According to an embodiment of the present disclosure, there is provided a contact lens, wherein the composition of the contact lens includes a moisturizing agent, the moisturizing agent includes glucan, and the glucan in the composition of the contact lens includes 1,3-1,6-glucan. Let the weight percentage of glucan in the composition of the contact lens be Pc, and the average transmittance of the contact lens at 400 nm to 700 nm be T4070. Then, a contact lens is provided that satisfies 0.001% ≦ Pc ≦ 1.00% and 90% ≦ T4070.

[0005] According to another embodiment of the present disclosure, there is provided a contact lens product including the contact lens described in the previous paragraph and a buffer solution in which the contact lens is immersed.

[0006] According to another embodiment of the present disclosure, there is provided a contact lens, wherein the composition of the contact lens includes a humectant, the humectant includes glucan, and the glucan in the composition of the contact lens includes beta-glucan. When the weight percentage of glucan in the composition of the contact lens is Pc and the average transmittance of the contact lens at 450 nm to 630 nm is T4563, a contact lens satisfying 0.0001 ≤ Pc and 90% ≤ T4563 is provided.

[0007] According to another embodiment of the present disclosure, there is provided a contact lens product including the contact lens described in the previous paragraph.

[0008] According to another embodiment of the present disclosure, there is provided a contact lens product including a contact lens and a buffer solution in which the contact lens is immersed. The buffer solution includes a humectant, the humectant of the buffer solution includes glucan, and the glucan in the buffer solution includes beta-glucan. When the weight percentage of glucan in the buffer solution is Pb, a contact lens product satisfying 0.0001% ≤ Pb ≤ 5.00% is provided.

Mode for Carrying Out the Invention

[0009] One embodiment of the present disclosure is a contact lens, wherein the composition of the contact lens comprises a humectant containing glucan, and the glucan in the composition of the contact lens comprises 1,3-1,6-glucan, providing a contact lens. By using glucan with a high moisturizing effect as the humectant in the contact lens, the dissipation of moisture from the contact lens to the air is reduced, contributing to the improvement of the moisturizing power of the contact lens. In addition, since Ganoderma lucidum can retain moisture with 1,3-1,6-glucan with high moisturizing power, selecting 1,3-1,6-glucan rich in Ganoderma lucidum as the humectant of the contact lens contributes to maximizing the moisturizing power of the contact lens.

[0010] Another embodiment of the present disclosure is a contact lens, wherein the composition of the contact lens comprises a humectant containing glucan, and the glucan in the composition of the contact lens comprises Beta-glucan, providing a contact lens. By using glucan with a high moisturizing effect as the humectant in the contact lens, the dissipation of moisture from the contact lens to the air is reduced, contributing to the improvement of the moisturizing power of the contact lens. In addition, selecting Beta-glucan as the humectant of the contact lens contributes to further enhancing the moisturizing power of the contact lens.

[0011] According to the contact lens of the present disclosure, when the weight percentage of glucan in the composition of the contact lens is Pc, it can satisfy 0.001% ≦ Pc ≦ 1.00%. By limiting the weight percentage of glucan in the composition of the contact lens, the contact lens has both high moisturizing power and high visible light transmittance. Or, it can satisfy 0.0001% ≦ Pc ≦ 10.00%. Or, it can satisfy 0.0005% ≦ Pc ≦ 5.00%. Or, it can satisfy 0.003% ≦ Pc ≦ 0.10%. Or, it can satisfy 0.005% ≦ Pc ≦ 0.05%. Or, it can satisfy 0.006% ≦ Pc ≦ 0.02%. Or, it can satisfy 0.008% ≦ Pc ≦ 0.013%. Or, it can satisfy 0.0001% ≦ Pc.

[0012] According to the contact lens of the present disclosure, when the average transmittance of the contact lens at 400 nm to 700 nm is T4070, 90% ≤ T4070 can be satisfied. By satisfying the average transmittance of 400 nm to 700 nm, the contact lens maintains a high transmittance for the entire visible light. Or, 90.5% ≤ T4070 can be satisfied. Or, 91% ≤ T4070 can be satisfied. Or, 91.5% ≤ T4070 can be satisfied. Or, 92% ≤ T4070 can be satisfied. Or, 92.5% ≤ T4070 ≤ 100% can be satisfied.

[0013] According to the contact lens of the present disclosure, when the average transmittance of the contact lens at 450 nm to 630 nm is T4563, 90% ≤ T4563 can be satisfied. By satisfying the average transmittance of 450 nm to 630 nm, the contact lens maintains a high transmittance for visible light in a specific wavelength range. Or, 90.5% ≤ T4563 can be satisfied. Or, 91% ≤ T4563 can be satisfied. Or, 91.5% ≤ T4563 can be satisfied. Or, 92% ≤ T4563 can be satisfied. Or, 92.5% ≤ T4563 ≤ 100% can be satisfied.

[0014] According to the contact lens of the present disclosure, when the molecular weight of glucan in the composition of the contact lens is MWc, 10 kDa ≤ MWc ≤ 2000 kDa can be satisfied. By adding glucan with an appropriate molecular weight to the contact lens, it is possible to prevent glucan from inhibiting the transmission of visible light, and to increase the physical strength of the contact lens, contributing to the maintenance of the transmission effect of the contact lens and the stabilization of the structure of the contact lens. Or, 30 kDa ≤ MWc ≤ 1800 kDa can be satisfied. Or, 50 kDa ≤ MWc ≤ 1500 kDa can be satisfied. Or, 100 kDa ≤ MWc ≤ 1000 kDa can be satisfied. Or, 150 kDa ≤ MWc ≤ 700 kDa can be satisfied.

[0015] According to the contact lens of the present disclosure, when the molecular particle size of glucan in the contact lens composition is PSc, it can satisfy 50 nm ≤ PSc ≤ 5000 nm. By adding glucan with an appropriate molecular particle size to the contact lens, glucan can be effectively embedded in the polymerized network structure, and the loss of glucan can be reduced, contributing to the improvement of the moisturizing effective time of the contact lens. Or, it can satisfy 500 nm ≤ PSc ≤ 4000 nm. Or, it can satisfy 1000 nm ≤ PSc ≤ 3000 nm. Or, it can satisfy 1200 nm ≤ PSc ≤ 2500 nm. Or, it can satisfy 1500 nm ≤ PSc ≤ 2300 nm. Or, it can satisfy 1600 nm ≤ PSc ≤ 2100 nm.

[0016] According to the contact lens of the present disclosure, when the diameter of the contact lens is Dc, it can satisfy 13.8 mm ≤ Dc ≤ 14.5 mm. By designing an appropriate diameter of the contact lens, it is possible to avoid the lens displacement caused by too small a diameter and also avoid the corneal deformation caused by too large a diameter, contributing to the improvement of the wearing stability of the user. Or, it can satisfy 13 mm ≤ Dc ≤ 15 mm. Or, it can satisfy 13.5 mm ≤ Dc ≤ 14.8 mm. Or, it can satisfy 14.0 mm ≤ Dc ≤ 14.2 mm.

[0017] According to the contact lens of the present disclosure, Beta-glucan in the contact lens composition may contain 1,3-1,6-glucan. Since Ganoderma lucidum can retain moisture with 1,3-1,6-glucan having high moisturizing power, selecting 1,3-1,6-glucan rich in Ganoderma lucidum as the moisturizer of the contact lens contributes to the maximization of the moisturizing power of the contact lens.

[0018] According to the contact lens of the present disclosure, the contact lens may be a hydrogel contact lens, and its main monomer may be hydroxyethyl methacrylate. By using glucan in a hydrogel contact lens whose main monomer is hydroxyethyl methacrylate, it contributes to improving the comfort of wearing the hydrogel contact lens.

[0019] According to the contact lens of the present disclosure, the composition of the contact lens may further include an ultraviolet absorber or a blue light absorber, a pigment, an auxiliary agent, an antioxidant, and a myopia progression inhibitor. By adding an ultraviolet absorber, a blue light absorber, an auxiliary agent, an antioxidant, etc., adverse reactions such as eye damage and inflammation can be reduced, and the discomfort caused by the contact lens absorbing moisture on the eyeball surface can be reduced. Also, by adding a pigment, the beauty of the contact lens can be enhanced, and the willingness of the user to wear it can be increased. Furthermore, by adding a myopia progression inhibitor, the contact lens has the effect of controlling and delaying the degree of myopia, and the application range of the contact lens is expanded.

[0020] By arranging the respective technical features in the contact lens of the present disclosure in combination, corresponding effects can be achieved.

[0021] Another embodiment of the present disclosure provides a contact lens product including the contact lens described in the above embodiment.

[0022] Another embodiment of the present disclosure provides a contact lens product, including the contact lens described in the above embodiment and a buffer solution, and the contact lens is immersed in the buffer solution.

[0023] According to the contact lens product of the present disclosure, the buffer solution may contain a humectant, the humectant of the buffer solution may contain glucan, and the glucan in the buffer solution may contain Beta-glucan. Using glucan with a high moisturizing effect as the humectant of the buffer solution contributes to improving the comfort of wearing contact lenses, and using Beta-glucan as the humectant of the buffer solution contributes to further improving the comfort of wearing contact lenses.

[0024] According to the contact lens product of the present disclosure, when the weight percentage of glucan in the buffer solution is Pb, it can satisfy 0.0003% ≤ Pb ≤ 1.00%. Limiting the weight percentage of glucan in the buffer solution contributes to reducing the foreign body sensation when the user puts the contact lens into the eye. Or, it can satisfy 0.0001% ≤ Pb ≤ 5.00%. Or, it can satisfy 0.0005% ≤ Pb ≤ 0.50%. Or, it can satisfy 0.001% ≤ Pb ≤ 0.30%. Or, it can satisfy 0.003% ≤ Pb ≤ 0.10%. Or, it can satisfy 0.005% ≤ Pb ≤ 0.05%. Or, it can satisfy 0.0055% ≤ Pb ≤ 0.008%.

[0025] According to the contact lens product of the present disclosure, when the molecular weight of glucan in the buffer solution is MWb, it can satisfy 50 kDa ≤ MWb ≤ 1500 kDa. Since the molecular weight of glucan affects its effect as a humectant, adding glucan with an appropriate molecular weight to the buffer solution contributes to the balance between the comfort and foreign body sensation when wearing contact lenses. Or, it can satisfy 10 kDa ≤ MWb ≤ 2000 kDa. Or, it can satisfy 30 kDa ≤ MWb ≤ 1800 kDa. Or, it can satisfy 100 kDa ≤ MWb ≤ 1000 kDa. Or, it can satisfy 150 kDa ≤ MWb ≤ 700 kDa.

[0026] According to the contact lens product of the present disclosure, when the molecular particle size of glucan in the buffer solution is PSb, it can satisfy 500 nm ≤ PSb ≤ 4000 nm. By adding glucan with an appropriate molecular particle size to the buffer solution, the glucan is uniformly dispersed in the buffer solution, contributing to the improvement of the uniformity of the buffer solution. Or, it can satisfy 50 nm ≤ PSb ≤ 5000 nm. Or, it can satisfy 1000 nm ≤ PSb ≤ 3000 nm. Or, it can satisfy 1200 nm ≤ PSb ≤ 2500 nm. Or, it can satisfy 1500 nm ≤ PSb ≤ 2300 nm. Or, it can satisfy 1600 nm ≤ PSb ≤ 2100 nm.

[0027] According to the contact lens product of the present disclosure, when the water content of the contact lens is Cw, it can satisfy 54.5% ≤ Cw. By designing an appropriate water content of the contact lens, the balance between the comfort of wearing the contact lens and the moisturizing effect can be achieved. Or, it can satisfy 55.0% ≤ Cw ≤ 100%. Or, it can satisfy 55.5% ≤ Cw ≤ 60.0%.

[0028] According to the contact lens product of the present disclosure, Beta-glucan in the buffer solution may contain 1,3-1,6-glucan. Since Ganoderma lucidum can retain moisture with 1,3-1,6-glucan having a high moisturizing power, selecting 1,3-1,6-glucan rich in Ganoderma lucidum as a moisturizer for the buffer solution contributes to maximizing the comfort of wearing the contact lens.

[0029] According to the contact lens product of the present disclosure, the composition of the contact lens may contain a moisturizer, and the moisturizer of the composition of the contact lens may contain Beta-glucan. Selecting Beta-glucan as a moisturizer for the contact lens contributes to further improving the moisturizing power of the contact lens.

[0030] According to the contact lens product of the present disclosure, when the viscosity of the buffer solution is VI, VI ≤ 10 Pa·s can be satisfied. By designing an appropriate viscosity of the buffer solution, it is possible to prevent the buffer solution on the contact lens surface from making it difficult to blink, thereby reducing the discomfort of the user. Or, 0 Pa·s < VI ≤ 5 Pa·s can be satisfied. Or, 0.1 Pa·s ≤ VI ≤ 3 Pa·s can be satisfied. Or, 0.3 Pa·s ≤ VI ≤ 2 Pa·s can be satisfied. Or, 0.5 Pa·s ≤ VI ≤ 1.5 Pa·s can be satisfied. Or, 0.75 Pa·s ≤ VI ≤ 1.25 Pa·s can be satisfied. Or, 0.9 Pa·s ≤ VI ≤ 1.1 Pa·s can be satisfied.

[0031] According to the contact lens product of the present disclosure, when the pH value of the buffer solution is pHb, 7.3 ≤ pHb ≤ 7.5 can be satisfied. The pH value of the tear fluid is about 7.4. By designing a pH value of the buffer solution close to that of the tear fluid, acid-base neutralization between the buffer solution on the contact lens surface and the tear fluid can be avoided, contributing to the avoidance of adverse reactions. Or, 6.5 ≤ pHb ≤ 8 can be satisfied. Or, 6.8 ≤ pHb ≤ 7.8 can be satisfied. Or, 7.0 ≤ pHb ≤ 7.6 can be satisfied. Or, 7.35 ≤ pHb ≤ 7.45 can be satisfied.

[0032] According to the contact lens product of the present disclosure, when the osmotic pressure of the buffer solution is Ob, 0.280 osmol / kg·H 2 O ≤ Ob ≤ 0.350 osmol / kg·H 2 O can be satisfied. By designing an appropriate osmotic pressure of the buffer solution, it is possible to avoid the buffer solution on the contact lens surface from dehydrating and swelling the corneal epithelium, thereby reducing the discomfort of the user. Or, 0.285 osmol / kg·H 2 O ≤ Ob ≤ 0.340 osmol / kg·H 2 O can be satisfied. Or, 0.290 osmol / kg·H 2 O ≤ Ob ≤ 0.320 osmol / kg·H 2 O can be satisfied. Or, 0.295 osmol / kg·H 20 ≤ Ob ≤ 0.305 Osmol / kg·H 2 can satisfy O.

[0033] In the contact lens and contact lens product of the present disclosure, each technical feature can achieve corresponding effects when arranged in combination.

[0034] The contact lens composition described in the present disclosure may contain at least one, at least two, at least three, and at least four humectants. The contact lens composition may contain at least one, at least two, at least three, and at least four monomers. The contact lens composition may contain at least one, at least two, at least three, and at least four initiators. The contact lens composition may contain at least one, at least two, at least three, and at least four crosslinking agents. The contact lens composition may contain at least one, at least two, at least three, and at least four diluents. The contact lens composition may selectively contain at least one, at least two, at least three, and at least four ultraviolet absorbers or blue light absorbers. The contact lens composition may contain at least one, at least two, at least three, and at least four dyes. The contact lens composition may contain at least one, at least two, at least three, and at least four adjuvants. The contact lens composition may contain at least one, at least two, at least three, and at least four antioxidants. The contact lens composition may contain at least one, at least two, at least three, and at least four myopia progression inhibitors. The contact lens composition may be inside or on the surface of the contact lens. When the contact lens composition is inside the contact lens, it means that the contact lens composition is used as a material and becomes a contact lens by curing. When the contact lens composition is on the surface of the contact lens, it means that the contact lens composition is bonded or attached to the surface of the contact lens by methods such as coating or immersion.

[0035] The weight percentage of the contact lens composition described in the present disclosure refers to the weight percentage of each composition in the dried contact lens with respect to the contact lens body in the contact lens product after taking out the contact lens body from the buffer solution and completely dehydrating it.

[0036] The humectants of the contact lens composition described in the present disclosure may include glucan, polyethylene glycol-40 hydrogenated castor oil (PEG 40 Castor Oil), polyethylene glycol-400 (PEG 400), glycerin, allantoin, hyaluronic acid, ceramide, cholesterol, seabuckthorn oil, polyglutamic acid (γ-PGA), trehalose, alginic acid, hypromellose (HPMC), 2-methacryloyloxyethyl phosphorylcholine (MPC; 2-Methacryloyloxyethyl phosphorylcholine), etc., and salts thereof.

[0037] The glucan in the contact lens composition described in the present disclosure may have a D-type or L-type three-dimensional structure. The glucan may include alpha-glucan and beta-glucan. Alpha-glucan may include alpha-1-3-glucan, alpha-1-4-glucan, alpha-1-6-glucan, alpha-1-3 / 1-4-glucan, alpha-1,4-1,6-glucan, and alpha-1,3-1,6-glucan. The main chain of alpha-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond, and the branched chain of alpha-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond. Beta-glucan may include beta-1-3-glucan, beta-1-4-glucan, beta-1-6-glucan, beta-1-3 / 1-4-glucan, beta-1,4-1,6-glucan, and beta-1,3-1,6-glucan. The main chain of beta-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond, and the branched chain of beta-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond. The glucan in the contact lens composition may further include beta-1,3-1,6-D-glucan in Ganoderma lucidum polysaccharide. The main chain of beta-1,3-1,6-D-glucan is a 1,3 bond, and the branched chain of beta-1,3-1,6-D-glucan is a 1,6 bond. The extraction source of the glucan in the contact lens composition may be yeast, grains, fungi, plants, bacteria, algae, lichens, etc. The yeast as the extraction source of the glucan in the contact lens composition may be baker's yeast, Saccharomyces cerevisiae. The grains as the extraction source of the glucan in the contact lens composition may be barley, oats, wheat, rice. The fungi as the extraction source of the glucan in the contact lens composition may be Ganoderma lucidum, mushrooms, maitake, shiitake, Aspergillus niger. The plants as the extraction source of the glucan in the contact lens composition may be Aloe vera, Echinacea.

[0038] The molecular weight of glucan in the contact lens composition described in the present disclosure refers to the number average molecular weight of the entire glucan in the contact lens, and the formula is (Σ the molecular weight of glucan in the contact lens composition) / the total number of molecules.

[0039] The glucan molecular particle size in the contact lens composition described in the present disclosure refers to the median value of the molecular diameters of the entire glucan in the contact lens composition.

[0040] The type of contact lens described in the present disclosure may be a hydrogel contact lens or a silicone hydrogel contact lens. The hydrogel contact lens contains a hydrogel monomer. The silicone hydrogel contact lens contains a silicone hydrogel monomer. The main monomer of the contact lens refers to the monomer component with the highest weight percentage in the contact lens.

[0041] The hydrogel monomers of the contact lens described in the present disclosure may include hydroxyethyl methacrylate (HEMA; 2-Hydroxyethyl methacrylate), methacrylic acid (MAA; Methacrylic Acid), 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (GMA; Glycerol monomethacrylate), N-vinyl-2-pyrrolidone (NVP; N-Vinyl-2-pyrrolidinone), methyl methacrylate (MMA; Methyl methacrylate), N,N-dimethylacrylamide (DMAA; N,N-Dimethyl Acrylamide), glucan (Glucan), etc.

[0042] The hydrogel of the contact lens described in the content of the present disclosure may be a contact lens material classified into Group 1 by the US Food and Drug Administration (USFDA), that is, a nonionic polymer with a low water content (less than 50 weight percent), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, Tetrafilcon A, etc., but is not limited thereto. Or, the above hydrogel may be a contact lens material classified into Group 2 by the US Food and Drug Administration, that is, a nonionic polymer with a high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B, Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, Nesofilcon A, Omafilcon A, Samfilcon A, etc. Or, the above hydrogel may be a contact lens material of Group 3 classified by the US Food and Drug Administration, that is, an ionic polymer with a low water content (less than 50 weight percent), such as Deltafilcon A. Or, the above hydrogel may be a contact lens material classified into Group 4 by the US Food and Drug Administration, that is, an ionic polymer with a high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, Vifilcon A, etc.

[0043] The silicone hydrogel monomers of the contact lenses described in the present disclosure may be, but are not limited to, 2-hydroxyethyl methacrylate, glycerol monomethacrylate, methacrylic acid, 3-methacryloyloxypropyltris(trimethylsilyloxy)silane, N-vinyl-2-pyrrolidinone, N,N-dimethyl acrylamide, (3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane), or (3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane.

[0044] The silicone hydrogels of the contact lenses described in the present disclosure may be, but are not limited to, contact lens materials classified as Group 5 by the U.S. Food and Drug Administration, such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, Somofilcon A, etc.

[0045] The initiator of the contact lens described in the present disclosure may be, but is not limited to, 2-hydroxy-2-methyl-1-phenyl-1-propanone.

[0046] The crosslinking agent of the contact lens described in the present disclosure may be, but is not limited to, ethylene glycol dimethacrylate or trimethylol propane trimethacrylate.

[0047] The diluent of the contact lens described in the present disclosure may be polyethylene glycol 300, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, 1,4-butanediol, ethanol, isopropyl alcohol, glycerol, or 1-hexanol.

[0048] The ultraviolet (UV) absorbers of the contact lenses described in the present disclosure may be, but are not limited to, 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate, 4-methacryloxy-2-hydroxybenzophenone, 2-phenylethyl acrylate, 2-phenylethyl methacrylate, 2-[2-hydroxy-5-[2-(methacryloyloxy)ethyl]phenyl]-2H-benzotriazole, or 2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylate.

[0049] The blue light absorbers of the contact lenses described in the present disclosure may be, but are not limited to, 4-(phenyldiazenyl)phenyl methacrylate.

[0050] The dyes of the contact lenses described in the present disclosure may include anthocyanidin, beta-carotene, curcumin, luciferin, lutein, lycopene, phycobillin, phycoerythrim, phycocyanin, riboflavin (vitamin B2), zeaxanthin, photochromic dyes, thermochromic dyes, etc., and derivatives thereof.

[0051] The auxiliary agents for contact lenses described in the present disclosure may include antibiotics, bacteriostatic agents, antiviral agents, antifungal drugs, antiallergic agents, apomorphine, bromocriptine, dopamine receptor agonists, levodopa, quinpirole, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), surfactants, miotics, enzyme inhibitors, anaesthetics, vasoconstrictors, nutrients, etc.

[0052] The antioxidants for contact lenses described in the present disclosure may be vitamin A, vitamin C, vitamin E, uric acid, carotenoid, flavonoid compounds, resveratrol, selenomethionine, etc.

[0053] The myopia progression inhibitor for contact lenses described in the present disclosure may include cycloplegic agents, mydriatic agents (pupil dilating agents), selective / non-selective muscarinic receptor antagonists, etc., which have the effect of controlling, reducing, delaying, or preventing the worsening of myopia. For example, by blocking the M-type muscarinic receptors of the parasympathetic nerves, it can relax and paralyze the ciliary muscle that controls the pupil, thereby dilating the pupil. For example, atropine ((3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), atropine sulfate, cyclopentolate (2-(Dimethylamino)ethyl(1-hydroxycyclopentyl)(phenyl)acetate), cyclopentolate HCl, eucatropine (1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), homatropine ((3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), nuvenzepine, phenylephrine HCl, pirenzepine, raceanisodamine, rispenzepine, scopolamine ((1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), scopolamine hydrobromide, telenzepine, tropicamide (N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), etc., and salts thereof.

[0054] The structural configuration of the contact lens described in the present disclosure may be a single-layer lens or may be at least a two-layer lens. The color contact lens may, for example, have a two-layer configuration of a lens body layer and a color layer. The color contact lens may, for example, have a three-layer configuration of a lens body layer, a color layer, and an anti-drop protection layer. The color contact lens may, for example, have a four-layer configuration of a lens body layer, a first color layer, a second color layer, and an anti-drop protection layer. The color contact lens may, for example, have a five-layer configuration of a lens body layer, a first color layer, a second color layer, a third color layer, and an anti-drop protection layer. The color contact lens may, for example, have another five-layer configuration of a lens body layer, a first color layer, a partition layer, a second color layer, and an anti-drop protection layer.

[0055] The stable structure of the contact lens described in the present disclosure can have, for example, a rotational stability design such as a design with a thicker lower vertical weight, a balance design with thicker sides, an asymmetric balance design, a stability design with thinner upper and lower parts.

[0056] The functions of the contact lens described in the present disclosure may include myopia correction, hyperopia correction, presbyopia correction, astigmatism correction, myopia control delay, corneal reshaping, etc.

[0057] The average transmittance of the contact lens described in the present disclosure refers to the average value of each transmittance at integer wavelengths every 1 nm. The average transmittance from 400 nm to 700 nm is the average value of the transmittances every 1 nm in the wavelength range of 400 nm to 700 nm, that is, the average value of the transmittances from 400 nm, 401 nm, 402 nm, 403 nm to 700 nm. The average transmittance from 450 nm to 630 nm is the average value of the transmittances every 1 nm in the wavelength range of 450 nm to 630 nm, that is, the average value of the transmittances from 450 nm, 451 nm, 452 nm, 453 nm to 630 nm.

[0058] The water content of the contact lens described in the present disclosure is the water content calculated based on the weights of the contact lens before and after hydration with pure water in accordance with ISO 18369-4 (2017), and the formula is: water content = (weight after hydration - weight before hydration) / weight after hydration. Since the water content of the contact lens is affected by the type of buffer solution in which it is immersed, it is measured after the contact lens has been immersed for at least 24 hours.

[0059] The oxygen permeability of the contact lens described in the present disclosure is the oxygen permeability calculated by hydrating the contact lens with pure water in accordance with ISO 18369-4 (2017). Since the oxygen permeability of the contact lens is affected by the type of buffer solution in which it is immersed, it is measured after the contact lens has been immersed in the buffer solution for at least 24 hours.

[0060] The buffer solution described in the present disclosure may contain at least one, at least two, at least three, and at least four humectants. The buffer solution may contain at least one, at least two, at least three, and at least four cooling agents. The buffer solution may contain at least one, at least two, at least three, and at least four eye protection components. The buffer solution may contain at least one, at least two, at least three, and at least four buffering agents. The buffer solution may contain at least one, at least two, at least three, and at least four antibacterial agents. The buffer solution may contain at least one, at least two, at least three, and at least four antioxidants. The buffer solution may contain at least one, at least two, at least three, and at least four chelating agents. The buffer solution may contain at least one, at least two, at least three, and at least four surfactants.

[0061] The humectants of the buffer solution described in the present disclosure may include glucan, polyethylene glycol-40 hydrogenated castor oil (PEG 40 Castor Oil), polyethylene glycol-400 (PEG 400), glycerin, allantoin, hyaluronic acid, ceramide, cholesterol, seabuckthorn oil, polyglutamic acid (γ-PGA), trehalose, alginic acid, hypromellose (HPMC), 2-methacryloyloxyethyl phosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), etc., and salts thereof.

[0062] The three-dimensional structure of glucan in the buffer solution described in the present disclosure may be of the D-type or L-type. Glucan may include Alpha-glucan and Beta-glucan. Alpha-glucan may include Alpha-1-3-glucan, Alpha-1-4-glucan, Alpha-1-6-glucan, Alpha-1-3 / 1-4-glucan, Alpha-1,4-1,6-glucan, and Alpha-1,3-1,6-glucan. The main chain of Alpha-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond, and the branched chain of Alpha-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond. Beta-glucan may include Beta-1-3-glucan, Beta-1-4-glucan, Beta-1-6-glucan, Beta-1-3 / 1-4-glucan, Beta-1,4-1,6-glucan, and Beta-1,3-1,6-glucan. The main chain of Beta-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond, and the branched chain of Beta-glucan may be a 1,3 bond, a 1,4 bond, or a 1,6 bond. The glucan in the buffer solution may further include Beta-1,3-1,6-D-glucan in Ganoderma lucidum polysaccharide. The main chain of Beta-1,3-1,6-D-glucan is a 1,3 bond, and the branched chain of Beta-1,3-1,6-D-glucan is a 1,6 bond. The extraction source of glucan in the buffer solution may be yeast, grains, fungi, plants, bacteria, algae, lichens, etc. The yeast from which the glucan in the buffer solution is extracted may be baker's yeast, Saccharomyces cerevisiae. The grains from which the glucan in the buffer solution is extracted may be barley, oats, wheat, rice. The fungi from which the glucan in the buffer solution is extracted may be Ganoderma lucidum, mushrooms, maitake, shiitake, Aspergillus niger. The plants from which the glucan in the buffer solution is extracted may be Aloe vera, Echinacea.

[0063] The molecular weight of glucan in the buffer solution described in the present disclosure refers to the number average molecular weight of the entire glucan in the buffer solution, and the formula is (Σ glucan molecular weight in the buffer solution) / total number of molecules.

[0064] The glucan molecular particle size in the buffer solution described in the present disclosure refers to the median of the molecular diameters of the entire glucan in the buffer solution.

[0065] The cooling agent of the buffer solution described in the present disclosure has the effect of imparting a cooling sensation to the site of action. The cooling agent includes menthol, N,2,3-trimethyl-2-isopropylbutyramide (WS-23), N-ethyl-p-menthane-3-carboxamide (WS-3), ethyl 3-(p-menthane-3-carboxamido)acetate (WS-5), (1R,2S,5R)-N-(4-methoxyphenyl)-p-menthanecarboxamide (WS-12), N-ethyl-2,2-diisopropylbutanamide (WS-27), N-(1,1-dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide (WS-116), etc., and salts thereof.

[0066] The eye protection component of the buffer solution described in the present disclosure may include vitamin A, lutein, omega-3 fatty acid, anthocyanin, astaxanthin, carotene, blueberry extract, lecithin, or a combination thereof.

[0067] The buffer of the buffer solution described in the present disclosure may be a buffer salt, such as citrate, acetate, phosphate, borate, sulfate, carbonate, nitrate, chloride, or a combination thereof. The cation of the buffer salt may be sodium, potassium, magnesium, or calcium. More preferably, the buffer is tris(hydroxymethyl)aminopropanesulfonic acid (TAPS), N,N-bis(2-hydroxyethyl)glycine (Bicine), tris(hydroxymethyl)aminomethane (Tris), N-tris(hydroxymethyl)methylaminoacetic acid (Tricine), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid half sodium salt (HEPES), N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino)ethanesulfonic acid (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), dimethylarsinic acid (Cacodylate), 2-morpholinoethanesulfonic acid (MES), etc., and salts thereof.

[0068] The antibacterial agent of the buffer solution described in the present disclosure may include benzoic acid, sodium nitrite, calcium propionate, boric acid, sodium borate, methylparaben, DMDM hydantoin (DMDMH), silver ions (Ag+), polyhexamethylene biguanide (PHMB), etc., and salts thereof.

[0069] The antioxidant of the buffer solution described in the present disclosure may include vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, oxidized or reduced coenzyme Q10, glutathione, lipoic acid, carotene, lutein, dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), propyl gallate (PG), t-butylhydroquinone (TBHQ), etc., and salts thereof.

[0070] The chelating agents of the buffer solution described in the present disclosure may include ethylenediamine (en), 2,2'-bipyridine (bipy), 1,10-phenanthroline (phen), oxalic acid, ethylenediaminetetraacetic acid (EDTA), 1,2-bis(dimethylarsine)benzene (diars), etc., and their salts.

[0071] The surfactants of the buffer solution described in the present disclosure may include poloxamer 407 (KP407), sodium dodecyl sulfate (SDS), cetyltrimethylammonium bromide (CTAB), stearyltrimethylammonium chloride (STAC), potassium stearate, gum arabic, sodium alginate, etc., and their salts.

[0072] The viscosity of the buffer solution described in the present disclosure refers to the viscosity of the buffer solution and can represent the fluidity of the buffer solution. The viscosity measurement is performed using a viscometer or a microviscometer. The rotation axis may be selected according to the measurement volume and rotation speed. The rotation speed of the measurement may be selected from 0.01 rpm to 500 rpm, and the measurement volume is at least 1 mL or more. For the details of the measurement, follow the operation manual of the viscometer used.

[0073] The buffer solution described in the present disclosure may be used as a preservative solution for contact lens products, and may be used in eye wash solutions, moisturizing solutions, eye drops, eye medications, and contact lens cleaning solutions.

[0074] The contact lens products described in the present disclosure may be composed of a contact lens body, a buffer solution, and a package, and the contact lens body is immersed in the buffer solution. The contact lens described in the present disclosure represents the contact lens body. The contact lens body and the solution may contain a humectant, a monomer, a UV absorber, a blue absorber, beneficial agents, a dye, a myopia control agent, salts of a weak acid and its conjugate base, salts of a weak base and its conjugate acid, an anionic agent, a cationic agent, and other auxiliary agents. The package described in the present disclosure may be manufactured by combining a plastic container and an aluminum foil cover. The plastic container may be made of a biodegradable plastic including polypropylene (PP), polystyrene (PS), polyethylene terephthalate (PET), or polylactic acid (PLA), polyhydroxyalkanoates (PHA), or other degradable plastics. A biodegradable plasticizer may be mixed into the biodegradable plastic to achieve modification or a modification effect. The aluminum foil cover of the present invention may be made of a composite aluminum foil material coated with plastic.

[0075] Unless otherwise noted, the measurement environment described in the present disclosure is a temperature of 25°C and a humidity of 50%.

[0076] Based on the above embodiments, specific examples will be given below and described in detail.

[0077] <First Comparative Example>

[0078] The contact lens product of the first comparative example includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0079] The contact lens of the first comparative example is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant, but neither the humectant in the contact lens composition nor the humectant in the buffer solution contains glucan.

[0080] The contact lens of the first comparative example is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. When the water content of the contact lens is Cw, Cw = 54.07%.

[0081] <First Example>

[0082] The contact lens product of the first example includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0083] The contact lens of the first example is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant, but the humectant in the contact lens composition contains glucan, and the humectant in the buffer solution does not contain glucan.

[0084] Refer to Table 1, which shows the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the first embodiment. Here, Pc is the weight percentage of glucan in the composition of the contact lens, MWc is the molecular weight of glucan in the composition of the contact lens, PSc is the molecular particle size of glucan in the composition of the contact lens, Cw is the water content of the contact lens, Dc is the diameter of the contact lens, T4070 is the average transmittance of the contact lens at 400 nm to 700 nm, T4563 is the average transmittance of the contact lens at 450 nm to 630 nm, Pb is the weight percentage of glucan in the buffer solution, MWb is the molecular weight of glucan in the buffer solution, PSb is the molecular particle size of glucan in the buffer solution, VI is the viscosity of the buffer solution, pHb is the pH value of the buffer solution, and Ob is the osmotic pressure of the buffer solution.

[0085]

Table 1

[0086] Since the definitions of the parameters in each of the following examples are all the same as those in Table 1 of the first embodiment, they will not be repeatedly described below.

[0087] <Second Embodiment>

[0088] The contact lens product of the second embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0089] The contact lens of the second embodiment is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. However, the humectant in the composition of the contact lens contains glucan, and the humectant in the buffer solution does not contain glucan.

[0090] Refer to Table 2, which shows the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the second embodiment.

[0091]

Table 2

[0092] <Third Embodiment>

[0093] The contact lens product of the third embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0094] The contact lens of the third embodiment is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. However, the humectant in the composition of the contact lens does not contain glucan, and the humectant in the buffer solution contains glucan.

[0095] Refer to Table 3, which shows the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the third embodiment.

[0096]

Table 3

[0097] <Fourth Embodiment>

[0098] The contact lens product of the fourth embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0099] The contact lens of the fourth embodiment is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. Both the humectant in the composition of the contact lens and the humectant in the buffer solution contain glucan.

[0100] Refer to Table 4, which shows the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the fourth embodiment.

[0101]

Table 4

[0102] <Fifth Embodiment>

[0103] The contact lens product of the fifth embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0104] The contact lens of the fifth embodiment is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a moisturizing agent, and the buffer solution contains a moisturizing agent. However, both the moisturizing agent in the contact lens composition and the moisturizing agent in the buffer solution contain glucan.

[0105] Refer to Table 5, which shows the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the fifth embodiment.

[0106]

Table 5

[0107] The present disclosure has been disclosed as above based on the embodiments, but it does not limit the present disclosure. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the protection scope of the present disclosure is based on what is defined in the appended claims.

Claims

1. A contact lens, The contact lens composition includes a moisturizing agent containing a glucan, and the glucan in the contact lens composition includes 1,3-1,6-glucan; The weight percentage of the glucan in the contact lens composition is Pc, and the average transmittance of the contact lens at 400 nm to 700 nm is T4070, 0.001%≦Pc≦1.00%; A contact lens that satisfies 90%≦T4070.

2. The weight percentage of the glucan in the contact lens composition is Pc, 2. The contact lens according to claim 1, wherein 0.003%≦Pc≦0.10% is satisfied.

3. The molecular weight of the glucan in the contact lens composition is designated as MWc, The contact lens according to claim 1, which satisfies 10 kDa≦MWc≦2000 kDa.

4. The molecular particle size of the glucan in the contact lens composition is represented as PSc, The contact lens according to claim 1, which satisfies 50 nm≦PSc≦5000 nm.

5. If the diameter of the contact lens is Dc, The contact lens according to claim 1, which satisfies 13.8 mm≦Dc≦14.5 mm.

6. The contact lens of claim 5 , wherein the contact lens is a hydrogel contact lens and contains hydroxyethyl methacrylate as a monomer.

7. The contact lens composition comprises: an ultraviolet absorbing agent or a blue light absorbing agent; A pigment and Adjuvants, Antioxidants, Myopia progression inhibitors, The contact lens of claim 6 further comprising:

8. A contact lens according to claim 1 ; a buffer solution in which the contact lens is immersed; Contact lens products including:

9. the buffer solution comprises a humectant, the humectant in the buffer solution comprises a glucan, and the glucan in the buffer solution comprises a beta-glucan; If the weight percentage of the glucan in the buffer solution is Pb, 9. The contact lens product according to claim 8, wherein the content of Pb satisfies 0.0003%≦Pb≦1.00%.

10. If the molecular weight of the glucan in the buffer solution is MWb, 10. The contact lens product according to claim 9, wherein 50 kDa≦MWb≦1500 kDa is satisfied.

11. If the molecular particle size of the glucan in the buffer solution is PSb, The contact lens product according to claim 10, which satisfies 500 nm≦PSb≦4000 nm.

12. If the water content of the contact lens is Cw, The contact lens product according to claim 11, which satisfies 54.5%≦Cw.

13. A contact lens, The contact lens composition includes a moisturizer including a glucan, and the glucan in the contact lens composition includes a beta-glucan; The weight percentage of the glucan in the contact lens composition is Pc, and the average transmittance of the contact lens at 450 nm to 630 nm is T4563, 0.0001%≦Pc; A contact lens that satisfies 90%≦T4563.

14. The contact lens of claim 13, wherein the beta-glucan in the contact lens composition comprises 1,3-1,6-glucan.

15. The weight percentage of the glucan in the contact lens composition is Pc, The contact lens according to claim 14, wherein 0.0005%≦Pc≦5.00% is satisfied.

16. The molecular weight of the glucan in the contact lens composition is designated as MWc, The contact lens according to claim 15, wherein 30 kDa≦MWc≦1800 kDa is satisfied.

17. The molecular particle size of the glucan in the contact lens composition is represented as PSc, The contact lens according to claim 16, which satisfies 500 nm≦PSc≦4000 nm.

18. A contact lens product comprising the contact lens of claim 13.

19. Contact lenses and a buffer solution in which the contact lens is immersed; Including, the buffer solution comprises a humectant, the humectant in the buffer solution comprises a glucan, and the glucan in the buffer solution comprises a beta-glucan; If the weight percentage of the glucan in the buffer solution is Pb, A contact lens product that satisfies 0.0001%≦Pb≦5.00%.

20. If the weight percentage of the glucan in the buffer solution is Pb, 20. The contact lens product according to claim 19, wherein the content of Pb is 0.001%≦Pb≦0.30%.

21. 21. The contact lens product of claim 20, wherein the beta-glucan in the buffer solution comprises 1,3-1,6-glucan.

22. 20. The contact lens product of claim 19, further comprising a humectant in said contact lens composition, said humectant in said contact lens composition comprising a beta-glucan.

23. If the molecular weight of the glucan in the buffer solution is MWb, 20. The contact lens product of claim 19, wherein 10 kDa≦MWb≦2000 kDa.

24. If the molecular particle size of the glucan in the buffer solution is PSb, 24. The contact lens product of claim 23, wherein 50 nm≦PSb≦5000 nm is satisfied.

25. If the viscosity of the buffer solution is VI, 25. The contact lens product of claim 24, wherein VI is less than or equal to 10 Pa·s.

26. If the pH value of the buffer solution is pHb, 26. The contact lens product according to claim 25, wherein 7.3≦pHb≦7.5 is satisfied.

27. If the osmotic pressure of the buffer solution is Ob, 0.280 osmol / kg H ２ O≦Ob≦0.350 osmol / kg H ２ 27. The contact lens product of claim 26, which satisfies O.

28. The contact lens composition includes a moisturizer, and the moisturizer of the contact lens composition includes a glucan; where Pc is the weight percentage of the glucan in the contact lens composition, T4070 is the average transmittance of the contact lens at 400 nm to 700 nm, T4563 is the average transmittance of the contact lens at 450 nm to 630 nm, MWc is the molecular weight of the glucan in the contact lens composition, PSc is the molecular particle size of the glucan in the contact lens composition, Dc is the diameter of the contact lens, Pb is the weight percentage of the glucan in the buffer solution, MWb is the molecular weight of the glucan in the buffer solution, PSb is the molecular particle size of the glucan in the buffer solution, VI is the viscosity of the buffer solution, pHb is the pH value of the buffer solution, and Ob is the osmotic pressure of the buffer solution. 0.008%≦Pc≦0.013%; 92.5%≦T4070; 92.5%≦T4563; 150 kDa≦MWc≦700 kDa; 1600 nm≦PSc≦2100 nm; 14.0 mm≦Dc≦14.2 mm, 0.0055%≦Pb≦0.008%; 150 kDa≦MWb≦700 kDa; 1600 nm≦PSb≦2100 nm; 0.9 Pa·s≦VI≦1.1 Pa·s; 7.35≦pHb≦7.45; 0.295 osmol / kg H ２ O≦Ob≦0.305 osmol / kg H ２ 20. The contact lens product of claim 19, which satisfies O.